Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Drops By 17.7%

enGene Holdings Inc. (NASDAQ:ENGN) saw a significant decline in short interest during the month of February. As of February 27th, there was short interest totaling 1,235,753 shares, a decline of 17.7% from the February 12th total of 1,501,696 shares. Currently, 2.1% of the company’s shares are short sold. Based on an average daily trading volume, of 119,320 shares, the short-interest ratio is presently 10.4 days. Based on an average daily trading volume, of 119,320 shares, the short-interest ratio is presently 10.4 days. Currently, 2.1% of the company’s shares are short sold.

enGene Stock Performance

Shares of enGene stock opened at $7.25 on Wednesday. The firm has a market cap of $485.64 million, a PE ratio of -3.22 and a beta of -0.29. The company has a quick ratio of 11.75, a current ratio of 11.75 and a debt-to-equity ratio of 0.09. enGene has a 52 week low of $2.65 and a 52 week high of $12.25. The business’s fifty day simple moving average is $9.34 and its 200-day simple moving average is $8.20.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.11. Equities analysts forecast that enGene will post -1.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on ENGN shares. Oppenheimer dropped their target price on enGene from $33.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, March 11th. Jefferies Financial Group started coverage on shares of enGene in a research report on Friday, January 30th. They set a “buy” rating and a $28.00 price target on the stock. Citigroup reissued a “market outperform” rating on shares of enGene in a report on Monday, January 5th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of enGene in a research report on Monday, March 9th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $27.00 target price on shares of enGene in a research note on Monday, March 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, enGene currently has a consensus rating of “Moderate Buy” and an average target price of $22.86.

Institutional Investors Weigh In On enGene

A number of institutional investors have recently made changes to their positions in the stock. PFS Partners LLC lifted its holdings in shares of enGene by 22.2% in the 4th quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock worth $99,000 after acquiring an additional 2,000 shares during the last quarter. Millennium Management LLC increased its holdings in enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after purchasing an additional 7,472 shares during the last quarter. Raymond James Financial Inc. increased its holdings in enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after purchasing an additional 7,932 shares during the last quarter. Cresset Asset Management LLC purchased a new stake in enGene in the second quarter valued at approximately $36,000. Finally, Paloma Partners Management Co purchased a new stake in enGene in the second quarter valued at approximately $38,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.